Compare Neurocrine Biosciences Inc (NBIX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Energy Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Energy Select Sector SPDR Fund trades at $65.16 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 2.8× Neurocrine Biosciences Inc's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| NBIX | XLE | |
|---|---|---|
Market Cap | $14.36B | $40.84B |
Volume | 1,237,180 | 50,409,268 |
Sector | Health | — |
52-Week High | $185.50 | $65.93 |
52-Week Low | $123.10 | $42.61 |
Typical Hold Time | 23 Days | 67 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
XLE trades at $65.27, up 2.98% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI at 70.16. The ETF, heavily concentrated in oil and gas, benefits from rising oil prices above $100 amid Middle East tensions and supply constraints. Recent news highlights strategic oil reserve releases and diesel price pressures, influencing energy sector volatility.
Outlook remains tied to oil price dynamics, with upside from sustained geopolitical risks but downside if crude reverses. Risks include oil market volatility and potential Fed rate hikes. Analyst sentiment is mixed, balancing energy sector strength against overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
